Advances in pharmacotherapy for hyperphosphatemia in renal disease (Q38587575)

4 September 2017

Advances in pharmacotherapy for hyperphosphatemia in renal disease (English)

1 reference

4 September 2017

0 references

1

Goce Spasovski

1 reference

PubMed ID

26374200

4 September 2017

language of work or name

English

0 references

publication date

16 September 2015

1 reference

Expert Opinion on Pharmacotherapy

4 September 2017

1 reference

4 September 2017

16

1 reference

4 September 2017

2589-2599

1 reference

4 September 2017

17

1 reference

Normal and pathologic concentrations of uremic toxins

4 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

A bench to bedside view of uremic toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Phosphate metabolism in chronic kidney disease: from pathophysiology to clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Bone health and vascular calcification relationships in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Meta-analysis of small trials: proceed with caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Effects of phosphate binders in moderate CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Pharmacology, efficacy and safety of oral phosphate binders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Economic evaluation of sevelamer in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Mortality in kidney disease patients treated with phosphate binders: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

Use of phosphate-binding agents is associated with a lower risk of mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1092521

10.1517/14656566.2015.1092521

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference

PubMed ID

26374200